Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
IL2
Name:
interleukin 2
Location:
04q27
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT00049725 | Daclizumab to Treat Chronic Immune Thrombocytopenia | View | |
| NCT00257907 | Immune Response to Mycobacterium Tuberculosis Infection | View | |
| NCT00521287 | Impaired Immunity in Patients With Cancer Influence of Cancer Stage Chemotherapy and Cytomegalovirus Infection | View | |
| NCT00539695 | Low Dose IL-2 Hematopoietic Stem Cell Transplantation IL2 for GVHD | View | |
| NCT00582790 | Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer | View | |
| NCT00590824 | Pilot hu1418-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma | View | |
| NCT00942058 | Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer | View | |
| NCT00912418 | Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor GM-CSF - in - Adjuvant Followed by Systemic Low-dose-interleukin-2 IL-2 Administration in Patients With High Risk Melanoma | View | |
| NCT04217343 | NCAMR-CAMR Allosure Study | View | |
| NCT01604031 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells Lenalidomide | View | |
| NCT01723306 | Phase IIPilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas | View | |
| NCT03123016 | Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo | View | |
| NCT00027937 | Combination Chemotherapy Peripheral Stem Cell Transplantation and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma | View | |
| NCT03625635 | Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment | View | |
| NCT04133233 | Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder | View | |
| NCT05222347 | Immunomodulatory and Preventive Effects of Olive Leaf Tea Against COVID-19 | View | |
| NCT00604357 | CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment | View | |
| NCT01058538 | A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours | View | |
| NCT01055522 | Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma | View | |
| NCT06217731 | Inflammatory Markers in Saliva of Patients With Burning Mouth Syndrome | View | |
| NCT05104567 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer Master Protocol Pegathor Gastrointestinal 203 | View | |
| NCT00200577 | Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma | View | |
| NCT03209869 | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu1418-IL2 | View | |
| NCT03823365 | Blinatumomab Expanded T-cells BET in Indolent Non-Hodgkin LymphomasChronic Lymphocytic Leukemia | View | |
| NCT05339217 | Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus | View | |
| NCT00082758 | hu1418-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma | View | |
| NCT01131364 | Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients | View | |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | View | |
| NCT00109863 | Hu1418-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma | View | |
| NCT00040170 | Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer | View | |
| NCT00053976 | Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease | View | |
| NCT00502034 | Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma | View | |
| NCT00277758 | Safety Study of Low Dose Interleukin 2 IL-2 Plus PEG-IFNRBV In Chronic Hepatitis C Virus Genotype I | View | |
| NCT00283829 | Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer | View | |
| NCT04404127 | Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients | View | |
| NCT02769767 | Polymorphisms of Interleukins Glypican and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis | View | |
| NCT01988506 | Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases | View | |
| NCT00415818 | Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer | View | |
| NCT01995344 | TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment | View | |
| NCT00553618 | Adjuvant Combined Interleukin 2 Proleukin and DTIC Dacarbazine in High-risk Melanoma Patients | View | |
| NCT01840046 | Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata | View | |
| NCT00931138 | Treatment of Acute Myeloid Leukemia AML in Adults 50 to 70 Years Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2 | View | |
| NCT04678518 | Inflammatory Markers Dynamics in Response to Extra-corporeal Membrane Oxygenator Decannulation | View | |
| NCT05610228 | Study of the Metabolism in the Lymphatic Niche of CLL | View | |
| NCT00003750 | Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors | View | |
| NCT01253096 | Intratumoral Application of L19IL2 in Patients With Malignant Melanoma | View | |
| NCT02300623 | Intermittent ART in Primary HIV Infection | View | |
| NCT01334515 | Biological Therapy Sargramostim and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma | View | |
| NCT02411253 | Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes | View | |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study | View | |
| NCT05153070 | Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes | View | |
| NCT01874288 | A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL | View | |
| NCT05218408 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | View | |
| NCT02076646 | A Phase III Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | View | |
| NCT02086721 | Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor | View | |
| NCT02478099 | MPDL3280A-treatment-IST-UMCG | View | |
| NCT02569463 | Low-dose IL-2 Interleukin-2 Treatment in Macrophage Activation SyndromeMAS | View | |
| NCT02659657 | Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation | View | |
| NCT02735850 | Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer ImmunoSABR | View | |
| NCT01830673 | Regulatory T-cells After Subcutaneous Immunotherapy | View | |
| NCT01833767 | Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma | View | |
| NCT02957019 | A Phase III Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma DLBCL | View | |
| NCT02997150 | Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2 a Pilot Study | View | |
| NCT02389231 | Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment | View | |
| NCT03308786 | HIV Reservoir Reduction With Interleukin-2 | View | |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | View | |
| NCT06130826 | Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer | View | |
| NCT04630769 | FT516 and IL2 With Enoblituzumab for Ovarian Cancer | View | |
| NCT03705403 | IMMUNOtherapy and Stereotactic ABlative Radiotherapy IMMUNOSABR a Phase II Study | View | |
| NCT03776643 | Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy | View | |
| NCT06413680 | A First-In Human FIH Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies | View | |
| NCT06427694 | Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes Follow-up Study | View | |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | View | |
| NCT01853358 | Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation | View | |
| NCT04357444 | Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 | View | |
| NCT04378972 | Anti-inflammatory Effect of Curcumin Homotaurine Vitamin D3 on Human Vitreous in Patients With Diabetic Retinopathy | View | |
| NCT04562129 | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | View | |
| NCT05821153 | Low Dose IL2 Immunotherapy in AD | View | |
| NCT04979884 | Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital | View | |
| NCT05471271 | IL-2 PET Imaging in Advanced Solid Tumours | View | |
| NCT00616564 | Phase II Trial of IL-2 With Priming and GM-CSF in Patients With Advanced Melanoma | View | |
| NCT00014092 | Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery | View | |
| NCT05605665 | Low-dose Interleukin-2 and Rapamycin on sjögrens Syndrome | View | |
| NCT00720135 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | View | |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy ACT Using an IL2 Analog ANV419 vs High Dose IL2 After Tumor Infiltrating Lymphocytes TIL Therapy in Patients With Melanoma NSCLC and Cervical Cancer PragmaTIL | View | |
| NCT00859131 | Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists | View | |
| NCT00069030 | Safety of and Immune Response to an HIV Vaccine VRC-HIVDNA009-00-VP Administered With Interleukin-2Immunoglobulin IL-2Ig DNA Adjuvant in Uninfected Adults | View | |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors | View | |
| NCT06640413 | A Study to Evaluate the Safety and Preliminary Signs of Efficacy of 177LuLu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors | View | |
| NCT02054884 | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | View | |
| NCT01147380 | Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation | View | |
| NCT01198522 | Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients | View | |
| NCT01266785 | Infliximab Regulatory T Cells IL2 and Crohns Disease | View | |
| NCT00020254 | Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer | View | |
| NCT01353833 | Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes | View | |
| NCT00006244 | Melphalan Peripheral Stem Cell Transplantation and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | View | |
| NCT02424396 | Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis | View | |
| NCT00250861 | Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin IL-2 vs Rituximab Alone for Non-Hodgkins Lymphoma | View | |
| NCT04977453 | GI-101 As a Single Agent or in Combination with Pembrolizumab Lenvatinib or Local Radiotherapy in Advanced Solid Tumors | View | |
| NCT02151903 | Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL | View | |
| NCT00000664 | Safety and Efficacy of Polyethylene Glycolated IL-2 PEG IL-2 Plus Zidovudine in HIV Positive Asymptomatic and Symptomatic Individuals | View | |
| NCT05271318 | Oncolytic Adenovirus Coding for TNFa and IL2 TILT-123 With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer | View | |
| NCT02169609 | Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma | View | |
| NCT00291369 | Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis | View | |
| NCT00006033 | Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer | View | |
| NCT01517347 | Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation | View | |
| NCT01124734 | High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma | View | |
| NCT01212887 | Treated Blood Cells Cyclophosphamide Fludarabine Phosphate and Aldesleukin in Treating Patients With Cancer | View | |
| NCT01383148 | Phase IIBIII Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer | View | |
| NCT02258815 | CH1418 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma | View | |
| NCT01493453 | A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy | View | |
| NCT04077684 | Efficacy and Safety of Low-dose IL-2 in Patients With SLE a Multicenter Randomised Placebo-controlled Trial | View | |
| NCT04163094 | Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With Neo-Adjuvant Chemotherapy | View | |
| NCT00321113 | Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys | View | |
| NCT00477906 | M-Vax Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma | View | |
| NCT00707759 | Steroid Withdrawal in Pediatric Renal Transplant Impact on Growth Bone Metabolism and Acute Rejection | View | |
| NCT02455908 | IL-2 for Multi Drug Resistant Nephrotic Syndrome | View | |
| NCT02522117 | Atorvastatin in the Recipients Kidney Graft From a Living Donor | View | |
| NCT02557074 | TREg Activation in the Treatment of the PELADE Alopecia Areata | View | |
| NCT02796352 | A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy Efficacy and Biomarker Study | View | |
| NCT02922283 | IL2 Imaging in Metastatic Melanoma | View | |
| NCT02989714 | Phase IbII Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor Nivolumab In Metastatic Clear Cell Renal Cell Cancer | View | |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC | View | |
| NCT03304223 | IL2 Imaging in Renal Transplantation | View | |
| NCT03958383 | IT-hu1418-IL2 With Radiation Nivolumab and Ipilimumab for Melanoma | View | |
| NCT04009681 | A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors THOR-707-101 | View |